Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Dark Pool Levels

BPTS
Biophytis SA
stock NASDAQ

Inactive
Apr 25, 2024
8.22USD-15.285%(-1.48)18,549
Pre-market
Dec 31, 1969 7:00:00 PM EST
0.00USD-100.000%(-9.70)0
After-hours
Dec 31, 1969 7:00:00 PM EST
0.00USD0.000%(0.00)0
OverviewPrice & VolumeSplitsHistoricalExchange VolumeDark Pool LevelsDark Pool PrintsExchangesShort VolumeShort Interest - DailyShort InterestBorrow Fee (CTB)Failure to Deliver (FTD)ShortsTrendsNewsNews
Nov 2, 2021
06:16AM EDT  The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 05.55 A.M. EDT).   RTTNews
Oct 25, 2021
10:04AM EDT  Benzinga's Top Ratings Upgrades, Downgrades For October 25, 2021   Benzinga
06:19AM EDT  HC Wainwright & Co. Initiates Coverage On Biophytis with Buy Rating, Announces Price Target of $15   Benzinga
Oct 7, 2021
08:24AM EDT  The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results   Benzinga
Oct 6, 2021
05:00PM EDT  Biophytis to Restate Previously Issued Financial Statements   GlobeNewswire Inc
07:33AM EDT  The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal   Benzinga
02:00AM EDT  Biophytis to Host Virtual KOL Event on Sarconeos (BIO101) on its   GlobeNewswire Inc
Oct 4, 2021
05:00PM EDT  Biophytis Announces the Drawing of 2 New Tranches of ORNANE Under   GlobeNewswire Inc
02:00AM EDT  Biophytis Announces Promising Full Results From the SARA-INT Phase   GlobeNewswire Inc
Sep 30, 2021
07:43AM EDT  The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug   Benzinga
06:30AM EDT  The following are some of the stocks making big moves in Thursday's pre-market trading (as of 6.15 A.M. EDT).   RTTNews
Sep 29, 2021
02:00AM EDT  Biophytis to Present Full Results From the SARA-INT Phase 2b Trial   GlobeNewswire Inc
Sep 21, 2021
08:20AM EDT  The Daily Biotech Pulse: Aprea Jumps On ESMO Presentation, Verrica Sinks On Regulatory Setback, Aerie CEO Quits, J&J Touts Positive COVID-19 Booster Shot Data   Benzinga
Sep 17, 2021
02:00AM EDT  Biophytis Reports H1 2021 Financial Results and Provides Business   GlobeNewswire Inc
Sep 15, 2021
02:00AM EDT  Biophytis Announces DMC Second Interim Analysis Efficacy Results   GlobeNewswire Inc
Sep 14, 2021
02:00AM EDT  Biophytis to Attend Key Upcoming Investor Events and Industry   GlobeNewswire Inc
Sep 9, 2021
02:00AM EDT  -- Rob van Maanen MD, MBA, FFPM, becomes Chief Medical Officer, member of the Executive Committee   GlobeNewswire Inc
Aug 16, 2021
08:36AM EDT  DMC Recommends Biophytis Continue Sarconeos COVID-19 Study   Benzinga
02:00AM EDT  Biophytis Receives Favorable Recommendation From Data Monitoring   GlobeNewswire Inc
Aug 13, 2021
05:00PM EDT  Biophytis Announces the Issue of 4,950,000 New Shares in a Capital   GlobeNewswire Inc
Aug 11, 2021
08:14AM EDT  The Daily Biotech Pulse: FDA Rejects FibroGen's Anemia Drug, Crinetics Gains On Positive Readout, BioCryst Withdraws Public Offering   Benzinga
Aug 10, 2021
07:55AM EDT  The Daily Biotech Pulse: Arcturus Soars On COVID-19 Vaccine Updates, Merck's Keytruda On Track For More Label Expansions, Eliem Debuts   Benzinga
Aug 2, 2021
06:24AM EDT  Biophytis Stock Gains As Sarconeos High Dose Improves Gait Speed Versus Placebo In Patients With Muscle Loss Due To Aging   Benzinga
02:00AM EDT  -- Sarconeos (BIO101) at the highest dose (350 mg bid) showed a clinically meaningful improvement in the 400-meter walk test (400MWT), the primary endpoint of the study -- Sarconeos (BIO101) showed a very good safety profile at the doses of 175 mg bid and of 350 mg bid with no Serious Adverse Events (AE) related to the product   GlobeNewswire Inc
Jul 20, 2021
08:20AM EDT  The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street   Benzinga
Jul 19, 2021
05:00PM EDT  Judgment Rendered on July 16, 2021 in the Proceedings Between   GlobeNewswire Inc
Jul 16, 2021
07:37AM EDT  The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study   Benzinga
Jul 12, 2021
11:10AM EDT  Biophytis Stock Is Trading Higher On Encouraging Preclinical Data From COVID-19 Study With Sarconeos   Benzinga
02:00AM EDT  Biophytis Presents Positive Preclinical Data on Sarconeos (BIO101)   GlobeNewswire Inc
Jul 9, 2021
07:36AM EDT  The Daily Biotech Pulse: Lilly, Morphic's Positive Data At ECCO, Humanigen's COVID Treatment Gets Expedited Review In UK, TransCode IPO   Benzinga
Jul 8, 2021
07:45AM EDT  The Daily Biotech Pulse: Priority Review For Amgen's Asthma Treatment, Evaxion Reports Positive Skin Cancer Readout, Quidel Recalls Lyra COVID-19 Test   Benzinga
02:02AM EDT  -- Claude Allary to be member of Board of Directors -- Benoit Canolle is appointed Chief Business Officer -- Jean Mariani, Chairman of Biophytis Scientific Committee to take over the Chief Medical Officer role   GlobeNewswire Inc
Jul 7, 2021
07:41AM EDT  The Daily Biotech Pulse: Opiant Spikes On Data, OncoSec Rallies On Merck Collaboration, XBiotech Special Dividend   Benzinga
Jun 30, 2021
05:00PM EDT  Results of Biophytis SARA-INT Phase 2 Trial with Sarconeos   GlobeNewswire Inc
05:00PM EDT  Biophytis Secures the Manufacturing of Sarconeos (BIO101) for   GlobeNewswire Inc
Jun 22, 2021
08:12AM EDT  The Daily Biotech Pulse: Sanofi, Translate Bio Start Early Stage Seasonal Flu Vaccine Study, Dr. Reddy's Launches Generic Vascepa, Halozyme Strikes Licensing Deal   Benzinga
Jun 18, 2021
08:00PM EDT  Biophytis announces new convertible bond financing for up to   GlobeNewswire Inc
Jun 9, 2021
09:14AM EDT  The Daily Biotech Pulse: Lyra Gains On Positive Regulatory Outcome, FDA Nod For Pfizer's Prevnar Vaccine, Merck Inks COVID-19 Treatment Supply Deal With US   Benzinga
May 28, 2021
08:02AM EDT  The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq   Benzinga
May 12, 2021
02:00AM EDT  -- This 2nd interim analysis is to be performed by the independent DMC (Data Monitoring Committee) based on safety and efficacy data -- The Company is to report the recommendation from the DMC based on its review of second interim analysis by end of Q2 2021, subject to any COVID-19-related delays   GlobeNewswire Inc
May 11, 2021
02:00AM EDT  BIOPHYTIS - Results of the Combined General Meeting on May 10, 2021   GlobeNewswire Inc
Apr 30, 2021
02:00AM EDT  Biophytis Second Combined General Meeting to   GlobeNewswire Inc
Apr 29, 2021
08:15AM EDT  The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx   Benzinga
02:00AM EDT  -- DeepTech funding supports advanced and highly differentiating biotech projects with significant commercial potential -- Biophytis plans to initiate Phase 1 clinical trial in the second half of 2021   GlobeNewswire Inc
Apr 27, 2021
02:00AM EDT  Biophytis - Convening of Another Combined General Meeting at a   GlobeNewswire Inc
Apr 26, 2021
02:00AM EDT  Biophytis Gives Operational Perspectives on its Sarconeos (BIO101)   GlobeNewswire Inc
Apr 13, 2021
05:00PM EDT  BIOPHYTIS Identifies False Report Regarding COVA study   GlobeNewswire Inc
08:16AM EDT  The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug   Benzinga
Apr 1, 2021
07:46AM EDT  The Daily Biotech Pulse: Pfizer-BioNTech Preps For BLA Filing, Sonoma Surges, BioXcel Readout, Ortho Clinical Lands Contract   Benzinga
Mar 26, 2021
07:28AM EDT  The Daily Biotech Pulse: FDA Nod For Astellas, Seagen, Gilead Get Positive Regulatory Tidings From Europe, 3 IPOs   Benzinga
Mar 25, 2021
07:58AM EDT  The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut   Benzinga
Mar 22, 2021
05:39AM EDT  BIOPHYTIS Independent Data Monitoring Committee Delivered Favorable Opinion for its Phase 2-3 COVA Study on COVID-19   Benzinga
03:00AM EDT  -- The Company receives a favorable opinion from the DMC on the safety of Sarconeos (BIO101) in the COVA study following first interim analysis -- Patient enrollment has now reached 97 of the 155 planned for the second interim analysis -- A total of 28 clinical centers are now opened and recruiting in the United States, Brazil, France & Belgium.   GlobeNewswire Inc
Mar 19, 2021
06:00PM EDT  Judgment of the Paris Commercial Court of March 16, 2021 in the   GlobeNewswire Inc
Mar 10, 2021
10:09PM EST  Legally required documents for shareholders votes are available on Biophytis website   GlobeNewswire Inc
Feb 26, 2021
02:00AM EST  Biophytis Reports 2020 Full Year Results   GlobeNewswire Inc
Feb 19, 2021
07:25AM EST  The Daily Biotech Pulse: Novavax Vaccine Supply Deal, Orphan Drug Designation For Travere, COVID-19 Boost For Quidel, Opko   Benzinga
Feb 17, 2021
02:00AM EST  Biophytis Announces Expansion of Patient Recruitment for Part 2 of   GlobeNewswire Inc
Feb 15, 2021
02:00AM EST  -- ADS Offering of $20.1 million in gross proceeds closed on February 12, 2021. -- Biophytiss ADSs began trading on the Nasdaq Capital Market on February 10, 2021.   GlobeNewswire Inc
Feb 10, 2021
10:04AM EST  Biophytis Shares Open For Trade At $18.50; IPO Priced At $16.75/Share   Benzinga
09:16AM EST  Biophytis Announces Trading Resumption of its Ordinary Shares and   GlobeNewswire Inc
02:00AM EST  Biophytis Announces Pricing of $20.1 Million U.S. Initial Public   GlobeNewswire Inc
Feb 9, 2021
11:47AM EST  The IPO Week Ahead   Benzinga


Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC